UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PCSK9 Inhibition could be Effective for Acute Myocardial Infarction

Current medicinal chemistry, 2022-01, Vol.29 (6), p.1016-1026

2022

Volltextzugriff (PDF)

Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update

European heart journal, 2018-02, Vol.39 (7), p.503-507

2018

Volltextzugriff (PDF)

Lipoprotein(a): the revenant

European heart journal, 2017-05, Vol.38 (20), p.1553-1560

2017

Volltextzugriff (PDF)

Lipid management in ACS: Should we go lower faster?

Atherosclerosis, 2018-08, Vol.275, p.368-375

2018

Volltextzugriff (PDF)

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease

The New England journal of medicine, 2022-11, Vol.387 (20), p.1855-1864

2022

Volltextzugriff (PDF)

Cardiovascular risk and testosterone – from subclinical atherosclerosis to lipoprotein function to heart failure

Reviews in endocrine & metabolic disorders, 2021-06, Vol.22 (2), p.257-274

2021

Volltextzugriff (PDF)

Identifying familial hypercholesterolemia in acute coronary syndrome

Current opinion in lipidology, 2016-08, Vol.27 (4), p.375-381

2016

Volltextzugriff (PDF)

Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors

European heart journal, 2017-03, Vol.38 (11), p.814-824

2017

Volltextzugriff (PDF)

Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)

The American heart journal, 2022-09, Vol.251, p.61-69

2022

Volltextzugriff (PDF)

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

European heart journal, 2017-08, Vol.38 (29), p.2245-2255

2017

Volltextzugriff (PDF)

The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism

Circulation (New York, N.Y.), 2020-05, Vol.141 (20), p.1600-1607

2020

Volltextzugriff (PDF)

Is there a shift from cardiovascular to cancer death in lipid-lowering trials? A systematic review and meta-analysis

PloS one, 2024-02, Vol.19 (2), p.e0297852

2024

Volltextzugriff (PDF)

Prevalence and outcomes of heart failure phenotypes in patients with atrial fibrillation

International journal of cardiology, 2024-10, Vol.412, p.132320, Article 132320

2024

Volltextzugriff (PDF)

Challenges in the Management of Atrial Fibrillation With Subclinical Hyperthyroidism

Frontiers in endocrinology (Lausanne), 2022-01, Vol.12, p.795492-795492

2022

Volltextzugriff (PDF)

Lipid-Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta-Analysis of Exclusion Criteria

Journal of the American Heart Association, 2023-01, Vol.12 (1), p.e026551-e026551

2023

Volltextzugriff (PDF)

Association between resistin levels and cardiovascular disease events in older adults: The health, aging and body composition study

Atherosclerosis, 2016-02, Vol.245, p.181-186

2016

Volltextzugriff (PDF)

Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome

PloS one, 2018-04, Vol.13 (4), p.e0195174-e0195174

2018

Volltextzugriff (PDF)

Inflammation during acute coronary syndromes — Risk of cardiovascular events and bleeding

International journal of cardiology, 2019-07, Vol.287, p.13-18

2019

Volltextzugriff (PDF)

Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of the American Heart Association, 2024-02, Vol.13 (4), p.e030714-e030714

2024

Volltextzugriff (PDF)

PCSK9 inhibitors

Swiss medical weekly, 2015-04, Vol.145, p.w14094

2015

Volltextzugriff (PDF)

Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61

Cardiovascular diabetology, 2019-10, Vol.18 (1), p.142-142, Article 142

2019

Volltextzugriff (PDF)

Association between income and control of cardiovascular risk factors after acute coronary syndromes: an observational study

Swiss medical weekly, 2019-04, Vol.149, p.w20049

2019

Volltextzugriff (PDF)

Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial

Journal of the American Heart Association, 2020-05, Vol.9 (10), p.e015331

2020

Volltextzugriff (PDF)

1 – 25 von 273

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(244)
Mit Volltextzugriff
(196)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(159)
Life Sciences & Biomedicine
(143)
Humans
(118)
Cardiovascular System & Cardiology
(89)
Cardiac & Cardiovascular Systems
(85)
Female
(69)
Male
(64)
Middle Aged
(50)
Risk Factors
(50)
Aged
(49)
Prospective Studies
(38)
Acute Coronary Syndromes
(37)
Acute Coronary Syndrome
(28)
Prognosis
(26)
General & Internal Medicine
(23)
Lipids
(23)
Medicine, General & Internal
(23)
Cardiology
(21)
Treatment Outcome
(21)
Acute Coronary Syndrome - Diagnosis
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

PCSK9 Inhibition could be Effective for Acute Myocardial Infarction

Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update

Lipoprotein(a): the revenant

Lipid management in ACS: Should we go lower faster?

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease

Cardiovascular risk and testosterone – from subclinical atherosclerosis to lipoprotein function to heart failure

Identifying familial hypercholesterolemia in acute coronary syndrome

Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors

Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism

Is there a shift from cardiovascular to cancer death in lipid-lowering trials? A systematic review and meta-analysis

Prevalence and outcomes of heart failure phenotypes in patients with atrial fibrillation

Challenges in the Management of Atrial Fibrillation With Subclinical Hyperthyroidism

Lipid-Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta-Analysis of Exclusion Criteria

Association between resistin levels and cardiovascular disease events in older adults: The health, aging and body composition study

Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome

Inflammation during acute coronary syndromes — Risk of cardiovascular events and bleeding

Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes

Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

PCSK9 inhibitors

Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61

Association between income and control of cardiovascular risk factors after acute coronary syndromes: an observational study

Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial

Suchergebnisse filtern